Furthermore, accumulating evidence demonstrated that downregulation of IKZF3 (Aiolos) and IKZF1 (Ikaros), two members of the IKZF family, in malignant plasma cells as well as in adaptative and innate lymphocytes is key for the anti-myeloma activity of Immunomodulatory drugs (IMiDs) [37]. This evidence concerns the gene IKZF3 and plasma cell myeloma.